Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats

American Journal of Physiology - Endocrinology and Metabolism

Volumn 278, Issue 1 41-1, 2000, Pages

  Tavares, Wendy ^a   Drucker, Daniel J ^b,c   Brubaker, Patricia L ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Clearance; Degradation; Dipeptidyl peptidase IV; Kidney

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HORMONE METABOLISM; INTESTINE; KIDNEY CLEARANCE; MALE; MOUSE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; SEQUENCE HOMOLOGY;

EID: 0033970249     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.2000.278.1.e134     Document Type: Article

References (29)

1. Baines, A. D., and C. K. Wu. Physical factors influencing fluid reabsoption from Henle's loop. Can. J. Physiol. Pharmacol. 53: 224-230, 1975.
2. Brubaker, P. L., A. Crivici, A. Izzo, P. Ehrlich, C. H. Tsai, and D. J. Drucker. Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2. Endocrinology 138: 4837-4843, 1997.
3. Brubaker, P. L., A. Izzo, M. Hill, and D. J. Drucker. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am. J. Physiol. Endocrinol. Metab. 272: E1050-E1058, 1997.
4. Buhling, F., U. Junker, D. Reinhold, K. Neubert, L. Jager, and S. Ansorge. Functional role of CD26 on human B lymphocytes, Immunol. Lett. 45: 47-51, 1995.
5. Darmoul, D., C. Rouyer-Fessard, A. Blais, T. Voisin, C. Sapin, L. Baricault, C. Cibert, G. Geraud, A. Couvineau, M. Laburthe, and G. Trugnan. Dipeptidyl peptidase IV expression in rat jejunal crypt-villus axis is controlled at mRNA level. Am. J. Physiol. Gastrointest. Liver Physiol. 261: G763-G769, 1991.
6. Deacon, C. F., A. H. Johnsen, and J. J. Holst. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80: 952-957, 1995.
7. Deacon, C. F., L. B. Knudsen, K. Madsen, F. C. Wiberg, O. Jacobsen, and J. J. Holst. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41: 271-278, 1998.
8. Deacon, C. F., L. Pridal, L. Klarskov, M. Olesen, and J. J. Holst. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am. J. Physiol. Endocrinol. Metab. 271: E458-E464, 1996.
9. Drucker, D. J., P. Ehrlich, S. L. Asa, and P. L. Brubaker. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc. Natl. Acad. Sci. USA 93: 7911-7916, 1996.
10. Drucker, D. J., Q. Shi, A. Crivici, M. Sumner-Smith, W. Tavares, M. Hill, L. DeForest, S. Cooper, and P. L. Brubaker. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat. Biotechnol. 15: 673-677, 1997.
11. Drucker, D. J., B. Yusta, R. Boushey, L. DeForest, and P. L. Brubaker. Human [Gly2]-GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 276: G79-G91, 1999.
12. Frohman, L. A., T. R. Downs, E. P. Heimer, and A. M. Felix. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J. Clin. Invest. 83: 1533-1540, 1989.
13. Jeng, W., J. Chernenko, J. Giguere, S. St-Pierre, J. Joseph, M. B. Wheeler, and P. L. Brubaker. Biological activities of modified GLP-1 (Abstract). Endocr. Soc. P2-98: 274, 1998.
14. Kieffer, T. J., C. H. S. McIntosh, and R. A. Pederson. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136: 3585-3596, 1995.
15. Kuku, S. F., J. B. Jaspan, D. S. Emmanouel, A. Zeidler, A. I. Katz, and A. H. Rubenstein. Heterogeneity of plasma glucagon. Circulating components in normal subjects and patients with chronic renal failure. J. Clin. Invest. 58: 742-750, 1976.
16. Macnair, R. D. C., and A. J. Kenny. Proteins of the kidney microvillar membrane. Biochem. J. 179: 379-395, 1979.
17. Martin, R. A., D. L. Cleary, D. M. Guido, H. A. Zurcher-Neely, and T. M. Kubiak. Dipeptidyl peptidase IV (DPP-IV) from pig kidney cleaves analogs of bovine growth hormone-releasing factor (bGRF) modified at position 2 with Ser, Thr or Val. Extended DPP-IV substrate specificity? Biochim. Biophys. Acta 1164: 252-260, 1993.
18. McGuire, M. J., P. E. Lipsky, and D. L. Thiele. Purification and characterization of DP I from human spleen. Arch. Biochem. Biophys. 295: 280-288, 1992.
19. Mentlein, R., B. Gallwitz, and W. E. Schmidt. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214: 829-835, 1993.
20. Munroe, D. G., A. K. Gupta, P. Kooshesh, T. B. Vyas, G. Rizkalla, W. Wang, L. Demchyshyn, Z. Yang, R. K. Kamboj, H. Chen, K. McCallum, M. Sumner-Smith, D. J. Drucker, and A. Crivici. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc. Natl. Acad. Sci. USA 96: 1569-1573, 1999.
21. O'Dorisio, T. M., K. R. Sirinek, E. L. Mazzaferri, and S. Cataland. Renal effects on serum gastric inhibitory polypeptide (GIP). Metabolism 26: 651-656, 1977.
22. Orskov, C., J. Andreasen, and J. J. Holst. All products of proglucagon are elevated in plasma from uremic patients. J. Clin. Endocrinol. Metab. 74: 379-384, 1992.
23. Ruiz-Grande, C., J. Pintado, C. Alarcón, C. Castilla, I. Valverde, and J. M. López-Novoa. Renal catabolism of human glucagon-like peptides 1 and 2. Can. J. Physiol. Pharmacol. 68: 1568-1573, 1990.
24. Scott, R. B., D. Kirk, W. K. MacNaughton, and J. B. Meddings. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am. J. Physiol. Gastrointest. Liver Physiol. 275: G911-G921, 1998.
25. Tsai, C. H., M. Hill, S. L. Asa, P. L. Brubaker, and D. J. Drucker. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am. J. Physiol. Endocrinol. Metab. 273: E77-E84, 1997.
26. 633 to Arg) of dipeptidyl peptidase IV causes its retention and rapid degradation in the endoplasmic reticulum. Biochemistry 31: 11921-11927, 1992.
27. Walter, R., W. H. Simmons, and T. Yoshimoto. Proline specific endo- and exopeptidases. Mol. Cell. Biochem. 30: 111-127, 1980.
28. Watanabe, Y., and Y. Fujimoto. Deficiency of membrane-bound dipeptidyl aminopeptidase IV in a certain rat strain. Experientia 43: 400-401, 1987.
29. Yasushi, K., N. Fujii, H. Naka, and T. Nagatsu. Multiple forms of glycylprolyl dipeptidyl-aminopeptidase (dipeptidyl peptidase IV) in human sera from patients with hepatitis. Biomed. Res. (Tokyo) 3: 265-269, 1982.